Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ358 in Patients With Congenital Hyperinsulinism

NCT06208215 is registered in ClinicalTrials.gov with Rezolute as lead sponsor.

NCT NCT06208215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06208215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Study to Evaluate the Efficacy and Safety of RZ358 in Patients With Congenital Hyperinsulinism
Lead sponsor
Rezolute
Phase
Phase 3
Overall status
Active, not recruiting
Start date
January 11, 2024
Completion date
November 14, 2027
Enrollment
56 (estimated)
Sites
18

Conditions

As the registry lists them; a condition with its own page is linked.

congenital hyperinsulinism